Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion is expected to see double-digit growth in the next fiscal year, thanks to their successful launch of the AMDS and strong performance in their aortic stent and surgical sealant businesses. However, their preservation services segment has underperformed, and there are potential risks in terms of delays in clinical trials. The company is actively pursuing international expansion and has a strong product pipeline for future growth and potential acquisitions.

Bears say

Artivion is facing a negative outlook due to slowing revenue growth, weak international expansion, and potential delays in clinical trials or new product approvals which could result in disappointing sales and weaker operating margins. The company ended Q4/25 with $65M in cash and $215M in debt, and its recent valuation is based on a 4.6x EV/Sales multiple, a 15% premium to the mean 2026E mid-cap Med-Tech comp group, applied to estimated 2027 revenue of $555M.

Artivion (AORT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Artivion (AORT) has a Strong Buy consensus rating as of Apr 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.